Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q3B726
UPID:
RPA43_HUMAN
Alternative names:
DNA-directed RNA polymerase I subunit F; Twist neighbor protein
Alternative UPACC:
Q3B726; A0PJ45; B7Z724
Background:
DNA-directed RNA polymerase I subunit RPA43, also known as DNA-directed RNA polymerase I subunit F and Twist neighbor protein, plays a crucial role in the transcription of DNA into RNA, utilizing the four ribonucleoside triphosphates as substrates. It is a key component of RNA polymerase I, which is responsible for synthesizing ribosomal RNA precursors. Its association with RRN3/TIF-IA suggests a role in the recruitment of Pol I to rDNA promoters.
Therapeutic significance:
Understanding the role of DNA-directed RNA polymerase I subunit RPA43 could open doors to potential therapeutic strategies.